The hepatokine fetuin-A disrupts functional maturation of pancreatic beta cells

Felicia Gerst 1,2,3 · Elisabeth Kemter 4 · Estela Lorza-Gil 1,2,3 · Gabriele Kaiser 1,2,3 · Ann-Kathrin Fritz 2 · Rita Nano 5 · Lorenzo Piemonti 5 · Marie Gauder 6 · Andreas Dahl 7 · Silvio Nadalin 8 · Alfred Königsrainer 8 · Falko Fend 9 · Andreas L. Birkenfeld 1,2,3 · Robert Wagner 1,2,3 · Martin Heni 1,2,3 · Norbert Stefan 1,2,3 · Eckhard Wolf 4 · Hans-Ulrich Häring 1,2,3 · Susanne Ullrich 1,2,3

Received: 12 October 2020 / Accepted: 19 January 2021 / Published online: 25 March 2021
© The Author(s) 2021

Abstract
Aims/hypothesis Neonatal beta cells carry out a programme of postnatal functional maturation to achieve full glucose responsiveness. A partial loss of the mature phenotype of adult beta cells may contribute to a reduction of functional beta cell mass and accelerate the onset of type 2 diabetes. We previously found that fetuin-A, a hepatokine increasingly secreted by the fatty liver and a determinant of type 2 diabetes, inhibits glucose-stimulated insulin secretion (GSIS) of human islets. Since fetuin-A is a ubiquitous fetal glycoprotein that declines peripartum, we examined here whether fetuin-A interferes with the functional maturity of beta cells.

Methods The effects of fetuin-A were assessed during in vitro maturation of porcine neonatal islet cell clusters (NICCs) and in adult human islets. Expression alterations were examined via microarray, RNA sequencing and reverse transcription quantitative real-time PCR (qRT-PCR), proteins were analysed by western blotting and immunostaining, and insulin secretion was quantified in static incubations.

Results NICC maturation was accompanied by the gain of glucose-responsive insulin secretion (twofold stimulation), backed up by mRNA upregulation of genes governing beta cell identity and function, such as NEUROD1, UCN3, ABCC8 and CASR (Log2 fold change [Log 2FC] > 1.6). An active TGFβ receptor (TGFB)–SMAD2/3 pathway facilitates NICC maturation, since the TGFB inhibitor SB431542 counteracted the upregulation of aforementioned genes and de-repressed ALDOB, a gene disallowed in mature beta cells. In fetuin-A-treated NICCs, upregulation of beta cell markers and the onset of glucose responsiveness were suppressed. Concomitantly, SMAD2/3 phosphorylation was inhibited. Transcriptome analysis confirmed inhibitory effects of fetuin-A and SB431542 on TGFB-pathway- and SMAD2/3-regulated transcription. However, contrary to SB431542 and regardless of cMYC upregulation, fetuin-A inhibited beta cell proliferation (0.27 ± 0.08% vs 1.0 ± 0.1% Ki67-positive cells in control NICCs). This effect was sustained by reduced expression (Log 2FC ≤−2.4) of FOXM1, CENPA, CDK1 or TOP2A. In adult human islets fetuin-A abolished glucose responsiveness, i.e. 1.7- and 1.1-fold change over

© Springer
2.8 mmol/l glucose in control- and fetuin-A-cultured islets, respectively. In addition, fetuin-A reduced SMAD2/3 phosphorylation and suppressed expression of proliferative genes. Of note, in non-diabetic humans, plasma fetuin-A was negatively correlated ($p = 0.013$) with islet beta cell area.

**Conclusions/interpretation**

Our results suggest that the perinatal decline of fetuin-A relieves TGFBR signalling in islets, a process that facilitates functional maturation of neonatal beta cells. Functional maturity remains revocable in later life, and the occurrence of a metabolically unhealthy milieu, such as liver steatosis and elevated plasma fetuin-A, can impair both function and adaptive proliferation of beta cells.

**Data availability**

The RNAseq datasets and computer code produced in this study are available in the Gene Expression Omnibus (GEO): GSE144950; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144950

**Keywords**  Adaptive proliferation · Fetuin-A · FOXM1 · Functional maturity · Pancreatic beta cells · TGFβ–SMAD2/3

**Abbreviations**

- ALDOB Aldolase B
- BMP Bone morphogenic protein
- DEG Differentially expressed genes
- ECIT European Consortium for Islet Transplantation
- ECM Extracellular matrix
- GO Gene Ontology
- GSIS Glucose-stimulated insulin secretion
- HSA Human serum albumin
- IGT Impaired glucose tolerance
- IFG Impaired fasting glucose
- iPSC Induced pluripotent stem cell
- IR Insulin receptor
- Log2FC Log$_2$ fold change
- NICC Neonatal islet cell cluster
- RNAseq RNA sequencing
- qRT-PCR Reverse transcription quantitative real-time PCR
- STZ Streptozotocin
- TGFB TGFβ receptor
- TLR4 Toll-like receptor 4
Introduction

The functional characteristic of mature beta cells is glucose-stimulated insulin secretion (GSIS), defined as cell’s ability to secrete appropriate amounts of insulin in response to a stimulatory concentration of glucose [1, 2]. To achieve such a functional phenotype, neonatal beta cells undergo a tightly regulated process of maturation. A well-timed orchestrated upregulation of transcription factors, components of secretory machinery, proteins governing cell-cell and cell–extracellular matrix (ECM) interactions, as well as cell cycle inhibitors, are prerequisites for functional maturation [3–7]. Downregulation of genes abundantly expressed in immature beta cells complement the process [8]. The preservation of glucose responsiveness of adult beta cells is essential for healthy glucose homeostasis. However, GSIS declines with ageing or due to metabolic stress, resulting in insulin deficiency, which is the ultimate cause of diabetes onset. Growing evidence suggests that metabolic stress and insulin resistance curtail both endocrine identity and adaptive proliferation of beta cells [9].

Pancreatic endocrine specification is regulated by a plethora of signals including TGFβ–bone morphogenetic protein (BMP) [10]. In its most simple form, TGFβ–BMP signalling consists of receptor-mediated phosphorylation of SMAD transcription factors, a mandatory event for their nuclear translocation and activity. While the canonical TGFβ receptor (TGFBR) pathway relies on SMAD2/3, and BMP receptor activates SMAD1/5/8, there is crosstalk between the two signalling arms [11]. In addition, inhibitory SMAD6 and SMAD7 counteract receptor-mediated activation of SMAD transcription factors [12]. Previous work reported beneficial effects of TGFBR–SMAD signalling on beta cell function [10]. Thus, mice overexpressing SMAD7 in their islets developed diabetes, and induced pluripotent stem cell (iPSC)-derived beta cells treated with a TGFBR inhibitor prior to transplantation failed to restore normoglycaemia in recipient diabetic mice [13, 14].

Depending on cellular context, TGFBR signalling triggers either proliferation or differentiation, as the transcriptional outcome depends on post-translational modifications of SMADs, recruitment of co-factors and the epigenetic status of the chromatin [12]. In addition, inhibitory ligands compete for receptor binding [15]. Likewise, fetuin-A can bind TGFβ, thereby interfering with receptor activation [16]. Fetuin-A is a fetal glycoprotein that declines peripartum, but is increasingly secreted by hepatocytes of the fatty liver [17, 18]. Fetuin-A augments adipose tissue inflammation via activation of toll-like receptor 4 (TLR4), thereby being a major determinant of insulin resistance and type 2 diabetes [19, 20]. We previously found that fetuin-A inhibits GSIS in adult human islets [21].

Here, we investigated the mechanisms underlying the role of fetuin-A on beta cell maturation and proliferation. We used porcine neonatal islet cell clusters (NICCs), a primary cell system validated as a translational model for human islets [22]. In addition to their committed endocrine phenotype, NICCs possess intrinsic proliferative and maturation capacities, thereby being essentially different from adult beta cells, which are fully differentiated and refractory to proliferation.

Methods

Reagents and resources

Details of materials used are provided in the electronic supplementary material (ESM) Table 1.

Isolation and culture of NICCs

German Landrace and Landrace-Yorkshire pigs were bred in the animal breeding facility of the Chair for Molecular Animal Breeding and Biotechnology (Munich, Germany) and NICCs were isolated as previously described [23]. Porcine pancreas (2–12-day-old piglets) was minced in Hanks’ balanced salt solution (HBSS, see ESM Methods) supplemented with 0.25% BSA, 10 mmol/l HEPES, 100 U/ml penicillin and 0.1 mg/ml streptomycin, transferred to HBSS containing 2 mg/ml collagenase V, and incubated for 120 min at 37°C. The digest was filtered and cultured in maintenance medium (see ESM Methods). At culture day (d)5–6, NICCs were placed in maturation medium supplemented with 0.6 mg/ml human serum albumin (HSA; see ESM Methods) or with human fetuin-A (0.6 mg/ml) and cultured for an additional 5 days with medium change every second day. TGFβ1 (2 ng/ml), TLR4 inhibitor CLI-095 (5 μmol/l) or TGFβ1 inhibitor SB431542 (10 μmol/l) were added when indicated. Since FCS contains high amounts of fetuin-A, NICC maturation was conducted in FCS-free medium [24]. Domestic pig handling and NICCs isolation was approved by the veterinary authorities (district government of Bavaria) and was conducted in accordance with the German Animal Welfare Act.

Isolated human islets

Human islets (ESM Table 2) were procured through the European Consortium for Islet Transplantation (ECIT) and cultured overnight in CMRL1066 medium (see ESM Methods). Afterwards, the islets were transferred to FCS-free medium supplemented with 0.6 mg/ml human fetuin-A or HSA (control) and cultured for an additional 2 days. CLI-095 (5 μmol/l) and TGFβ1 (2 ng/ml) were added during the 2 days or the last 1 h of culture, respectively. Ethics approval for the use of human islets was obtained.
| NEUROD1 mRNA (2-ΔCt) | PDX1 mRNA (2-ΔCt) | SYT4 mRNA (2-ΔCt) | INS mRNA (2-ΔCt) | IL1B mRNA (2-ΔCt) |
|----------------------|--------------------|-------------------|------------------|-------------------|
| Mat. day             | HSA (mg/ml)        | Fet-A (mg/ml)     | CLI (µmol/l)     | Mat. day           | HSA (mg/ml)        | Fet-A (mg/ml)     | CLI (µmol/l)     |
|                      | 0.6                | 0.6               | -                | 0.6               | 0.6                | 0.6               | -                |
| 1                    | -                  | -                 | -                | -                 | -                  | -                 | -                |
| 5                    | 0.6               | 0.6               | -                | 0.6               | 0.6                | 0.6               | -                |
| 5                    | 0.6               | 0.6               | -                | 0.6               | 0.6                | 0.6               | -                |
| 5                    | 0.6               | 0.6               | -                | 0.6               | 0.6                | 0.6               | -                |

**Diabetologia (2021) 64:1358–1374**
from the Ethics Commission of the Medical Faculty of the University Hospital of Tuebingen (533/2010BO2 and 098/ 2017BO1) and from the ECIT centres. All experiments were performed in accordance with the abovementioned approvals, guidelines and regulations.

**Insulin secretion**

NICCs and human islets were incubated in KRB containing (in mmol/l): 135 NaCl, 4.8 KCl, 1.2 MgSO4, 1.2 KH2PO4, 1.3 CaCl2, 5 NaHCO3, 10 HEPES (pH 7.4) and supplemented with 0.5% BSA. The islets were pre-incubated for 1 h in KRB supplemented with 2.8 mmol/l glucose followed by 1 h incubation in KRB containing glucose and test substances as indicated. Secreton insulin and insulin content were measured by ELISA or radioimmunoassay.

**Measurement of secreted TGFβ-1**

At culture d5, NICCs were transferred to standard maturation medium (100 NICCs/3 ml) and cultured for an additional 5 days without medium change. On maturation days 1 (culture d6), 3 (culture d8) and 5 (culture d10) medium was collected for quantification of secreted TGFβ-1 and NICCs were lysed in RIPA buffer for protein measurement.

**Transcriptome analysis**

**RNA extraction and qRT-PCR** Total cellular RNA extracted from NICCs and human islets using a commercial kit was transcribed using random primers (Transcriptor First Strand kit, Roche, Germany). For reverse transcription quantitative real-time PCR (qRT-PCR), normalised gene expression was calculated as ratio of the cycle threshold (Ct) values of target vs housekeeping gene (RPS13) transcripts (2^ΔΔCt).

**NICC transcriptome profiling with RNA sequencing** The mRNA was isolated from 0.2 μg total RNA (RNA integrity number [RIN] ≥ 9) and subjected to RNA sequencing (RNAseq) workflow as described in ESM Methods: Transcriptome analysis.

**Affymetrix microarray of adult human islets**

The analysis was performed with RNA isolated from three distinct human islet preparations mixed in a ratio of 1:1:1. Therefore the differences in gene expression represent a mean of n = 3 independent islet preparations and all changes induced by fetuin-A are robust, donor-independent changes. Microarray analysis was performed using the Affymetrix GeneChip HG-U133 Plus2 GeneChip Array platform (Thermo Fischer Scientific, MA, USA) and primary data analysis was performed with Affymetrix software GeneChip Operating System (GCOS) v1.4.

**Human pancreatic resections**

Patients (n = 22 non-diabetic; n = 32 with impaired glucose tolerance [IGT]/impaired fasting glucose [IFG] and n = 24 with type 2 diabetes, ESM Table 3) undergoing surgery for removal of pancreatic tumours provided written informed consent. Collection of human material and the study was approved by the Ethic Commission of Medical Faculty of the University of Tuebingen (697/2011BO1 and 355/ 2012BO2). Fasting blood samples were collected prior to anaesthesia and used to assess metabolic traits. Tumour-free pancreatic tissue was dissected, immediately fixed in 10% neutral buffered formalin and further processed for insulin immunostaining. Classification of normal glucose tolerance, IGT/IFG or type 2 diabetes was performed according to clinical history, fasting glucose and HbA1c levels, using ADA criteria.

**Immunostaining**

Isolated human islet cells (ECIT donors), whole NICCs and NICC cryosections were fixed in 4% formalin, permeabilised with ice-cold 0.2–1% Triton-X-100-PBS, blocked with 10%
were excluded. Analysed by a trained scientist. No experiments and results were blinded using numbers and the slides blindy assigned for the treatments. For quantification, histological samples were served for quantification of islet beta cell areas (Fig. 7 and ESM Fig. 4) using ImageJ (version 1.53a, NIH, USA) software.

Western blotting

NICCs and human islets were lysed in RIPA buffer (see ESM Methods). Proteins were resolved on 8–12% SDS-PAGE and blotted onto nitrocellulose membranes. Membranes were blocked in Tris Buffered Saline (TBS) supplemented with 0.15% Tween-20 and 5% milk, incubated with primary antibodies (1:1000 in TBS supplemented with 0.15% Tween and 5% BSA), followed by incubation with horseradish peroxidase-coupled secondary antibody (1:2000 in 10% FCS-PBS, and incubated with primary antibodies against SMAD2/3, Ki67, p16/Ink4a or insulin (1:100 in 10% FCS-PBS), followed by incubation with anti-rabbit/anti-mouse Alexa-Fluor488/546-IgG (1:1000 in 10% FCS-PBS). Nuclei were stained with TOPRO3 or DAPI. Fluorescent imaging was performed with laser scanning confocal microscope (Leica Microsystems, Germany) or ApoTome System (Carl Zeiss Microscopy, Germany).

Tissue sections from formalin-fixed, paraffin-embedded human pancreatic resections were incubated overnight with anti-insulin antibody (1:1000) and visualised using the Opti-View DAB IHC detection system (Roche Ventana, Switzerland). Haematoxylin was used as counterstain. Light microscopy images were performed with an EVOS M5000 microscope (Thermo Fisher Scientific, Germany) and insulin-stained areas served for quantification of islet beta cell areas (Fig. 7 and ESM Fig. 4) using ImageJ (version 1.53a, NIH, USA) software.

Quantification and statistical analysis

Data are presented as mean ± SEM. The number (n) of replicates and independent experiments are given in the respective figure legends. Statistical analysis, except the RNASeq data (see ESM Methods: Transcriptome analysis), was performed with GraphPad Prism (version 8.4.0) using one-way ANOVA and Tukey’s post hoc testing. Differences were considered statistically significant at p < 0.05. Pathways and Gene Ontology (GO) enrichment analysis of RNAseq data were performed with the web version of the Ingenuity Pathway Analysis software (Qiagen, Germany; https://analysis.ingenuity.com/pa/) and with web-based application GOrilla (cbl-gorilla.cs.technion.ac.il; access date 20.07–23.07.2020), respectively.

Islets (pig and human) were randomly distributed and blindly assigned for the treatments. For quantification, histological samples were blinded using numbers and the slides analysed by a trained scientist. No experiments and results were excluded.

Results

Fetuin-A inhibits functional maturation of NICCs

To assess whether fetuin-A impacts on functional maturation of beta cells, NICCs were matured in HSA- or fetuin-A-containing medium. HSA at a concentration identical to that of fetuin-A (0.6 mg/ml) was used as control, since fetuin-A and HSA are plasma components sharing similar characteristics as Ca2+- and fatty acid-binding proteins [25, 26]. Successful maturation was confirmed by upregulation of INS, PDX1, NEUROD1, MAFA, GCK, SYT4 and SYT7 mRNAs, paralleled by the increased number of insulin- and PDX1-positive cells (maturation d5 vs d1; Fig. 1a–h). Fetuin-A prevented upregulation of the aforementioned beta cell markers, an effect unsusceptible to the TLR4 inhibitor CLI-095. However, CLI-095 inhibited fetuin-A-induced increase of IL1B mRNA (Fig. 1i). Fetuin-A also reduced the number of insulin/PDX1-positive cells as well as the protein amount of PDX1 (Fig. 1h, j, k).

Since HSA concentration was rather low and fetuin-A-containing medium was albumin-free, we assessed whether HSA per se interferes with NICC maturation. Neither omission of HSA nor the increase of HSA concentration (0.6 to 1.2 mg/ml) altered NICC maturation. Moreover, addition of HSA to fetuin-A (0.6 mg/ml each) did not counteract the inhibitory effect of fetuin-A (ESM Fig. 1a–g). Despite marked upregulation of functional beta cell genes, matured NICCs (HSA/maturation d5) acquired a modest GSIS (1.4-fold increase). Nonetheless, glucose responsiveness was significantly improved (twofold increase) in the presence of forskolin, an adenylyl cyclase activator that increases the intracellular level of cAMP, bypassing membrane receptors (Fig. 11 and ESM Fig. 1h). Fetuin-A-cultured NICCs were glucose unresponsive even in the presence of forskolin. Of

\[
\text{Fig. 2 Inhibition of TGFBR signalling impairs NICC maturation. NICCs were matured for 5 days in standard medium or in containing HSA + SB341542 or HSA + TGFβ-1 as indicated and described under Methods. (a–f) Relative mRNA levels (ΔCt vs RPS13) assessed by qRT-PCR of (a) CDKN2A (encoding p16/Ink4a), (f) NEUROD1, (g) SMAD7, (h) PDX1, (i) INS and (j) ALDOB, expressed as mean ± SEM of n = 4–5 independent NICC preparations. (b) Representative confocal images from n = 4 independent NICC preparations immunostained for P16/Ink4a (green) at the beginning (HSA/mat. d1) and at the end (HSA/ mat. d5) of maturation in standard medium; nuclei were stained with TOPRO3 (red); scale bar 100 μm. (c) TGFβ-1 (pg [μg protein]−1 day−1) secreted by NICCs into culture medium at maturation d1, d3 and d5 expressed as mean ± SEM of n = 8 distinct NICC preparations. (d, e, k–n) Representative western blots of (d, e) P-SMAD2/3 and SMAD2/3 and (k–n) ALDOB and respective quantitative analysis expressed as mean ± SEM of (d, e, k, l) n = 3 and (m, n) n = 4 independent NICC preparations; tubulin and GAPDH were used as loading controls. Significant effects (ANOVA) are *p < 0.05 vs maturation d1 (HSA/d1); †p < 0.05 vs maturation d5 (HSA/d5); ‡p < 0.05 vs TGFβ-1/d5. d, day; Mat. Maturation; SB, SB341542; TGFβ, TGFβ-1.
\]
note, forskolin-elevated insulin secretion was glucose independent (Fig. 11).

These results suggest that fetuin-A hinders functional maturation of neonatal beta cells in a TLR4-independent manner.

Role of TGFBR–SMAD2/3 signalling for NICC maturation

Postnatal maturation of beta cells is accompanied by upregulation of p16/Ink4a (also known as cyclin-dependent kinase
inhibitor 2A (encoded by CDKN2A)], a cell cycle inhibitor under positive regulation of TGFBR–SMAD2/3. NICC maturation (d5 vs d1) was accompanied by CDKN2A upregulation, while both immature (d1) and mature (d5) NICCs displayed p16/Ink4a-positive nuclei (Fig. 2a,b). Uptregulation of CDKN2A was mediated by TGFBR–SMAD2/3 signalling, as it was inhibited by SB431542 and augmented by TGFβ-1 (Fig. 2a).

TGFβ-dependent augmented of CDKN2A expression during maturation is further corroborated by TGFβ-1 accumulation in culture medium, indicating constitutive expression and release of TGFβ-1 (Fig. 2e and ESM Fig. 1i). The secreted ligand can activate TGFβ with subsequent SMAD2/3 phosphorylation and CDKN2A upregulation (Fig. 2a–e). On the contrary, SB431542 reduced SMAD2/3 phosphorylation, i.e. the lower SMAD2/3 phosphoprotein-band disappeared, while the upper one was minimally affected (Fig. 2d,e). NEUROD1 and SMAD7 were revealed to be regulated by TGFβ–SMAD2/3, since SB431542 reduced both SMAD mRNA levels and the increase of NEUROD1 mRNA levels during maturation (Fig. 2f,g). SB431542 affected neither PDX1 nor INS expression (Fig. 2h,i). An active TGFβ–SMAD2/3 pathway is essential for beta cell maturation, as endorsed by the observation that SB431542 increased, while TGFβ-1 decreased, the mRNA and protein levels of aldolase B (ALDOB), a marker of functionally immature as well as of human diabetic beta cells (Fig. 2j–n) [27, 28].

These findings indicate that selective expression of beta cell markers during NICC maturation requires an active TGFβ–SMAD2/3 pathway.

**Fetuin-A impairs TGFBR–SMAD2/3 signalling in NICCs**

Next, we examined whether the effect of fetuin-A on NICC maturation was mediated by inhibition of TGFβ–SMAD2/3 signalling. Indeed, fetuin-A inhibited phosphorylation of SMAD2/3 (Fig. 3a–c). In accordance, fetuin-A recapitulated the effects of SB431542 on SNAI1 and cMYC expression, two known targets of SMAD2/3 (Fig. 3d–h). Furthermore, fetuin-A counteracted upregulation of UCN3, ABCC8, PCSK1 and G6PC2, an effect also exerted by SB431542 (Fig. 3i–l).

To gain insight into the common and distinct effects of fetuin-A and SB431542 on NICC maturation, and to identify SMAD2/3-regulated genes potentially affected by fetuin-A, we performed comparative bulk RNAseq-based transcriptome analysis of NICCs cultured with fetuin-A, HSA, or HSA + SB431542. Using +1 < Log2FC < -1 and p < 0.05 adjusted for multiple comparisons as thresholds, we found 882 up- and 328 downregulated genes following maturation (HSA; d5 vs d1) (ESM Table 4). In the fetuin-A-treated NICCs (Fet-A/d5 vs HSA/d5) 423 genes were up- and 1198 were downregulated, while in the presence of SB431542, 156 and 289 genes were up- and downregulated, respectively (ESM Tables 5 and 6). In addition to the shared beta cell markers NEUROD1, UCN3, ABCC8, PCSK1 and CASR (Fig. 4a), fetuin-A inhibited a larger set of genes than SB431542, including terms controlling differentiation (PDX1, MAFA, MAFB), insulin secretion (G6PC2, SLC2A2, SLC30A8, SYT4/7/13, membrane receptors) and adaptive proliferation (FOXMI, CDKI, CENPA/F/E, TOP2A) (Fig. 4a,b).

A comparison of the gene sets altered by SB431542 and fetuin-A revealed 172 common targets, suggesting that fetuin-A regulates these genes via inhibition of TGFBR–SMAD2/3 signalling (ESM Fig. 2a). In accordance with reduced SMAD2/3 phosphorylation, fetuin-A altered expression of typical SMAD2/3 targets, such as cMYC, SNAI1, TGFB1 or POSTN (Fig. 4b). It is noteworthy that the effect of fetuin-A on gene expression was age-independent, although slightly reduced in NICCs from older piglets (12d vs 4d old animals; Fig. 4b).

To identify common contributors to the transcriptional phenotypes of fetuin-A- and SB431542-treated NICCs, the respective differentially expressed genes (DEGs) were subjected to upstream regulator analysis (Ingenuity). The analysis relies on coordinated changes which impact on downstream targets of these contributors, regardless of whether the contributor’s own expression is altered. z scores predict activation or inhibition of such regulators. While TGFβ1 emerged as the top ranking contributor, the analysis identified SMAD2/3, SP1, FOXMI1 and MAFB as transcriptional regulators inhibited by both fetuin-A and SB431542 (Fig. 4c).

These results endorse inhibition of TGFβ–SMAD2/3-dependent transcription as an important contributor to the phenotype of fetuin-A-treated NICCs.

To reveal cellular processes potentially affected by the DEGs, a GO overrepresentation analysis was performed. The maturation-upregulated gene set was enriched for terms related to insulin secretion, membrane potential, cell adhesion and cell–cell communication (Fig. 5a and ESM Fig. 2b). The fetuin-A-downregulated gene set was enriched for GO terms attributed to hormone level, cell adhesion, cell division and ECM organisation (Fig. 5b and ESM Fig. 2c). Similarly, the DEGs downregulated by SB431542 were enriched for terms associated with ECM organisation and cell adhesion (Fig. 5c and ESM Fig. 2d). Several GO terms were common for maturation-, fetuin-A- or SB431542-altered gene sets, indicating that fetuin-A and SB431542 impact on identical cellular processes, such as ECM organisation and cell adhesion. The GO ranking suggested regulation of insulin secretion as most probable consequence of gene upregulation upon maturation, while ECM organisation, cell adhesion and cell cycle processes were consequences of fetuin-A-downregulated genes (ESM Fig. 2b,c).

**Fetuin-A impairs NICC proliferation**

TGFβ–SMAD2/3 signalling inhibits beta cell proliferation via induction of p16/Ink4a. While SB431542 reduced the mRNA level of CDKN2A (see Fig. 2a), the transcriptome analysis suggested a stimulatory effect of fetuin-A on CDKN2A-dependent transcription (see Fig. 4c). On the other
hand, fetuin-A and SB431542 increased cMYC expression (see Fig. 3e–h), a proliferative gene under negative regulation of SMAD2/3. Therefore, we examined the effects of fetuin-A and SB431542 on beta cell proliferation in more detail.

In contrast to SB431542 and in spite of reduced SMAD2/3 phosphorylation, fetuin-A increased CDKN2A expression, an effect counteracted by the TLR4 inhibitor CLI-095 (Fig. 6a). Fetuin-A did not alter the cellular distribution of p16/Ink4a in
beta cells (Fig. 6b). Confirming the RNAseq data (Fig. 4b), fetuin-A reduced expression of genes regulating beta cell proliferation, i.e. PRLR1, FOXM1, CENPA, TOP2A and CDK1 (Fig. 6c–g). Distinct to fetuin-A, SB431542 did not alter the expression of these genes. In line with this expression pattern, fetuin-A reduced (0.27 ± 0.08%) while SB431542 (HSA + SB/d5 vs HSA/d5; n = 2) animals.

These findings suggest that fetuin-A limits the proliferative expansion of beta cell mass. Indeed, the fetuin-A-treated NICCs displayed significantly lower numbers of beta cells (i.e. insulin-positive), in comparison with control NICCs (14.4 ± 1.2% and 22.3 ± 1.1%, respectively) (Fig. 6j).

Despite increasing beta cell proliferation, SB431542 and proctolin had no effect on beta cell number (Fig. 6j).

**Fetuin-A impairs TGFBR signalling and glucose responsiveness of adult human islets**

In order to translate these results to humans we examined whether fetuin-A impacts on TGFBR–SMAD2/3 signalling in isolated islets from organ donors. In human islets cultured for 2 days with fetuin-A, basal and TGFβ–stimulated SMAD2/3 phosphorylation were inhibited (Fig. 7a–c). In accordance, fetuin-A reduced nuclear accumulation of SMAD2/3 in cultured islet cells (Fig. 7d). An Affymetrix-based transcriptome analysis of human islets cultured for
**Pathway analysis of RNA sequencing in NICCs.** RNAseq analysis of mRNA isolated from NICCs was performed as described under Methods. (a) DEGs downregulated upon culture with fetuin-A and (b) DEGs upregulated upon maturation in standard medium and in -fetuin-A. (c) GO Terms significantly enriched ($p \leq 10^{-4}$) in 2 days with fetuin-A revealed RANBP3L as the top upregulated gene, while POSTN, CDK1, CENPF, TOP2A, and TPX2 occupied prominent positions among the downregulated ones (Fig. 7f). Of note, the qRT-PCR analysis confirmed the fetuin-A-induced upregulation of RAN binding protein 3L (RANBP3L), a protein that regulates nuclear-cytosolic shuttling of SMADs (Fig. 7e, [29]). The fetuin-A-altered gene set was enriched in GO terms related to calcium transport and ECM organisation, and the GO ranking suggests calcium transport into the cytosol as functional consequence (Fig. 7g and ESM Fig. 3). Fetuin-A abolished glucose responsiveness of human islets (from 1.7-fold increase of secretion [$p < 0.05$] to 1.1-fold [$p > 0.05$]) by increasing basal secretion, an effect maintained in the islets co-treated with the TLR4 inhibitor CLI-095 (Fig. 7h).

Notably, we found a negative correlation of islet beta cell area with the level of plasma fetuin-A in non-diabetic humans ($p = 0.013$; Fig. 7i-k and ESM Fig. 4).

These results indicate that fetuin-A impairs functional maturity (i.e. GSIS, and TGFBR signalling) in adult islets. In addition, fetuin-A might compromise the adaptive increase of functional beta cell mass.

**Discussion**

Investigating maturation of porcine neonatal islets, we found that fetuin-A disrupts both functional maturation and adaptive proliferation of beta cells. Fetuin-A inhibits TGFBR–SMAD2/3 signalling, a pathway essential for adequate expression of critical functional genes, while it diminishes beta cell proliferation in a TGFBR–SMAD2/3-independent manner.

**TGFBR–SMAD2/3 pathway sustains functional maturation of beta cells**

During maturation, NICCs express and secrete TGFβ-1 which, in an autocrine/paracrine manner, stimulates TGFBR–SMAD2/3-dependent transcription, increasing CDKN2A expression. Thus, TGFBR–SMAD2/3 inhibition by SB431542 counteracted upregulation of CDKN2A, but also that of NEUROD1, UCN3 and ABCC8. Of note, TGFBR–SMAD2/3 signalling repressed ALDOB, a disallowed gene in mature beta cells and a marker of functionally immature as well as of diabetic beta cells [8, 27, 28]. These results document a positive role of the TGFBR–SMAD2/3 pathway for functional maturation of beta cells. In accordance, mice with beta cell-specific deletion of Smad2 display defective GSIS and overt diabetes along with increased islet proliferation and hyperplasia [30]. Likewise, iPSC-derived beta cells require active TGFBR–SMAD2/3 signalling for functional maturation, i.e. gain of glucose-responsive insulin secretion. In line with this, iPSC-derived...
**Diabetes (2021) 64:1358–1374**

### a

**CENPA mRNA (2^-ΔCt)**

| Mat. day | HSA (mg/ml) | Fet-A (mg/ml) | SB (µmol/l) |
|----------|-------------|---------------|-------------|
| 1        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |

### b

**Insulin+ cells (% of islet cells)**

### c

**PRKIR1 mRNA (2^-ΔCt)**

| Mat. day | HSA (mg/ml) | Fet-A (mg/ml) | SB (µmol/l) |
|----------|-------------|---------------|-------------|
| 1        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |

### d

**FOXMI4 mRNA (2^-ΔCt)**

| Mat. day | HSA (mg/ml) | Fet-A (mg/ml) | SB (µmol/l) |
|----------|-------------|---------------|-------------|
| 1        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |

### e

**CENPA mRNA (2^-ΔCt)**

| Mat. day | HSA (mg/ml) | Fet-A (mg/ml) | SB (µmol/l) |
|----------|-------------|---------------|-------------|
| 1        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |

### f

**TOP2A mRNA (2^-ΔCt)**

| Mat. day | HSA (mg/ml) | Fet-A (mg/ml) | SB (µmol/l) |
|----------|-------------|---------------|-------------|
| 1        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |

### g

**CDK1 mRNA (2^-ΔCt)**

| Mat. day | HSA (mg/ml) | Fet-A (mg/ml) | SB (µmol/l) |
|----------|-------------|---------------|-------------|
| 1        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |
| 5        | 0.6         | -             | -           |

### h

**Insulin Ki67 DAPI**

### i

**Ki67 / insulin+ cells (% of beta cells)**

| Mat. day | HSA (mg/ml) | Fet-A (mg/ml) | SB (µmol/l) | PRL (ng/ml) | TGFβ (ng/ml) |
|----------|-------------|---------------|-------------|-------------|--------------|
| 1        | 0.6         | -             | -           | -           | -            |
| 5        | 0.6         | -             | -           | -           | -            |
| 5        | 0.6         | -             | -           | -           | -            |
| 5        | 0.6         | -             | -           | -           | -            |
| 5        | 0.6         | -             | -           | -           | -            |

### j

**Insulin+ cells (% of islet cells)**

| Mat. day | HSA (mg/ml) | Fet-A (mg/ml) | SB (µmol/l) | PRL (ng/ml) | TGFβ (ng/ml) |
|----------|-------------|---------------|-------------|-------------|--------------|
| 1        | 0.6         | -             | -           | -           | -            |
| 5        | 0.6         | -             | -           | -           | -            |
| 5        | 0.6         | -             | -           | -           | -            |
| 5        | 0.6         | -             | -           | -           | -            |
| 5        | 0.6         | -             | -           | -           | -            |
since connexion-36 expression is required for Ca\(^{2+}\) oscillation. This expression may contribute to the low glucose responsiveness, an observation in conformity with the neonatal phenotype of metastatic human islets [1, 39]. In line with this, in human islets fetuin-A upregulated expression of TMEM27, a gene recently associated with beta cell juvenile phenotype [40].

We found an extensive fetuin-A- and SB431542-induced dysregulation of genes related to cell–cell communication, cell adhesion and ECM. TGFβ signalling is in fact the master regulator of ECM organisation, while ECM components such as matrix metalloproteinases (MMPs) activate latent TGFβ ligands. Moreover, there is increasing evidence that islet ECM determines beta cell function [41, 42]. Therefore, fetuin-A-induced inhibition of TGFβ signalling may impact on beta cell function also via alterations of islet ECM. One of the top genes downregulated by fetuin-A was the SMAD3 target POSTN (which encodes periosis), an ECM component secreted by islet pericytes and stellate cells. Whether ECM remodelling underlies the inhibitory effect of fetuin-A on human islet function needs further experimental evidence. Indeed, periosis was found to sustain beta cell regeneration and function recovery in STZ-treated mice [43–45].

Fetuin-A reduced phosphorylation and nuclear localisation of SMAD2/3 in human islet cells, and it upregulated RANBP3L, a chaperone involved in nuclear export of SMADs [29]. Since the epigenetic landscapes of neonatal and adult beta cells differ considerably, and SMAD action is subjected to epigenetic regulation [8], it is reasonable to assume that the fetuin-A-modulated TGFβ–SMAD pathway yields distinct outcomes in adult and neonatal islets. Yet, according to the GO ranking, cytosolic Ca\(^{2+}\) trafficking and ECM organisation are functional consequences of fetuin-A-altered gene expression in human islets. We previously showed that fetuin-A alters Ca\(^{2+}\) sensitivity of insulin secretion in adult human islets, an observation in conformity with its Ca\(^{2+}\)-binding ability [21].

\textbf{TGFβ–SMAD2/3 inhibition and fetuin-A exert opposing effects on beta cell proliferation}

Neonatal beta cells are proliferative and functionally immature [2, 46]. To achieve full glucose-responsive insulin secretion they undergo a maturation process accompanied by rapid decline of proliferative capacity [1, 40]. To the contrary, adult beta cells are differentiated and refractive toward proliferation, and they acquire an immature neonatal-like phenotype when primed to undergo cell cycling, i.e. following expression of non-oncogenic levels of cMYC [5]. In this respect, our results

\begin{itemize}
\item Fetuin-A inhibits beta cell proliferation. NICCs were cultured as described under Methods, (a–c–g) Relative mRNA levels (ΔC\(_i\) vs RPS13) assessed by qRT-PCR of (a) CDKN2A, (c) PRLR1, (d) FOXM1, (e) CENPA, (f) TOP2A and (g) CDK1 expressed as mean±SEM of \(n = 3\) independent NICC preparations. (b) Maximum intensity projections of NICCs immunostained for p16\(^{INK4a}\) (green) and insulin (red) preceding (HSA/mat. d1) and following maturation in standard medium (HSA/mat. d5) or in fetuin-A-containing medium (Fet-A/mat. d5); scale bar 200 μm. (h) Representative confocal microscopy pictures of NICCs immunostained for insulin (green) and Ki67 (blue) preceding (HSA/mat. d1) and following maturation in standard medium (HSA/mat. d5) or in medium containing fetuin-A (Fet-A/mat. d5). HSA + SB431542 (HSA + SB), or HSA + prolatin (10 ng/ml, HSA + PRL), as indicated; nuclei were stained with DAPI (red); scale bar 100 μm. (i–p) Percentage of (i) Ki67/insulin co-stained and (j) insulin-stained cells in NICCs cultured as indicated in (h). Results are expressed as mean±SEM of \(n = 3\) independent NICC preparations. Significant effects \((p < 0.05, \text{ANOVA})\) are \(*p < 0.05\) vs immature NICCs (HSA/ mat. d1); \(\dagger p < 0.05\) vs matured NICCs (HSA/ mat. d5). CLI, CLI-095 (TLR4 inhibitor); d, day; Fet-A, fetuin-A; Mat., maturation; PRL, prolactin; SB, SB431542
\end{itemize}
showing that fetuin-A diminished both functional maturation and proliferation of NICCs were unexpected.

Fetuin-A-induced upregulation of cMYC did not suffice to boost beta cell proliferation, since expression of CDKN2A, the potent inhibitor of beta cell proliferation, remained high [47]. Of note, the TLR4 inhibitor CLI-095 counteracted the fetuin-A-mediated increase of CDKN2A (see Fig. 6a). Fetuin-A is an endogenous ligand of TLR4 [19]; therefore contribution of this receptor to the effect of fetuin-A on CDKN2A cannot be excluded. Fetuin-A, a physiological inhibitor of insulin receptor (IR), reduced expression of FOXM1, a transcription factor acting downstream of IR and a master regulator of a proliferative pathway comprising TOP2A, CDK1, PLK1 and CENPA and also operating in human adult beta cells. Unlike cMYC-dependent proliferation, FOXM1-driven proliferation does not harm beta cell function, thereby allowing compensatory increase of functional beta cell mass [5, 48]. Indeed, we found a reduced number of proliferative beta cells in fetuin-A-treated NICCs.

TOP2A, CDK1, CENPF and TPX2 (red arrows, Fig. 7i) are top upregulated genes in proliferating beta cells, while reduced TPX2 expression was recently found in human islets exposed to glucolipotoxicity [49, 50]. Downregulation of these genes in fetuin-A-treated human islets suggests a persistent inhibitory effect of fetuin-A on proliferation. In line with this, in non-diabetic humans, plasma fetuin-A level was negatively correlated with beta cell area, suggesting that fetuin-A constrains expansion of functional beta cell mass required by an increased insulin demand.

Distinct to fetuin-A, SB431542 reduced CDKN2A expression and increased NICC proliferation, suggesting that CDKN2A downregulation is mandatory for beta cell proliferation [47]. However, inhibition of TGFBR impaired functional maturity of beta cells, i.e. cMYC and ALDOB upregulation, which might explain why SB431542 did not increase beta cell number (Fig. 6j). Thus, inhibition of this pathway is an unsustainable strategy for increasing beta cell mass.

In conclusion, we propose that fetuin-A is a negative modulator of function and proliferation of beta cells. The perinatal drop in fetuin-A production favours postnatal maturation and proliferation of neonatal beta cells. During adult life, a chronic fatty liver-induced elevation of serum fetuin-A impairs both functional maturity and the adaptive increase of adult beta cell mass, thereby accelerating the onset of type 2 diabetes.

Supplementary Information The online version contains peer-reviewed but unedited supplementary material available at https://doi.org/10.1007/s00125-021-05435-1.

Acknowledgements We acknowledge the skilled technical assistance of S. Haug and E. Metzinger (University Hospital of Tübingen, Tübingen, Germany) and of C. Blechinger (Faculty of Veterinary Medicine, Molecular Animal Breeding and Biotechnology, LMU Munich, Germany). We thank S. Wagner and L. Fritsche for their excellent help with the sampling of human pancreatic biopsies.

Data availability The RNAseq datasets and computer code produced in this study are available in the Gene Expression Omnibus (GEO): GSE144950; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144950

Funding Open Access funding enabled and organized by Projekt DEAL. This work was supported by a grant (2018–2019) from the German Center for Diabetes Research (DZD e.V.) awarded to FG and EK as well as by a grant (01GI0925) from the German Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD e.V.). Human islet isolation was supported by a JDRF Grant (JDRF award 31-2008-416).

Authors’ relationships and activities The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

Contribution statement FG, HUH, EW, NS, ALB, AK, SN, FF and SU designed the study. FG, RW, MH designed and performed the experiments and interpreted the data. EK, GK, ELG and AKF performed experiments. RN and LP isolated and provided the human islets and contributed to data acquisition. MG and AD performed and analysed the RNAseq data. FG and SU drafted the manuscript. All authors critically revised the manuscript and approved the final version.

FG is the guarantor of this work.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Henquin JC, Nenquin M (2018) Immaturity of insulin secretion by pancreatic islets isolated from one human neonate. J Diabetes Invest 9(2):270–273. https://doi.org/10.1111/jdi.12701
2. Blum B, Hrvatin S, Schuetz C, Bonal C, Rezania A, Melton DA (2012) Functional beta-cell maturation is marked by an increased glucose threshold and by expression of urocortin 3. Nat Biotechnol 30(3):261–264. https://doi.org/10.1038/nbt.2141
3. Huang C, Walker EM, Dadi PK et al (2018) Synaptotagmin 4 regulates pancreatic beta cell maturation by modulating the Ca(2+) sensitivity of insulin secretion vesicles. Dev Cell 45(3):347–361.e345. https://doi.org/10.1016/j.devcel.2018.03.013
4. Gu C, Stein GH, Pan N et al (2010) Pancreatic beta cells require NeuroD to achieve and maintain functional maturity. Cell Metab 11(4):298–310. https://doi.org/10.1016/j.cmet.2010.03.006
5. Puri S, Roy N, Russ HA et al (2018) Replication confers beta cell immaturity. Nat Commun 9(1):485. https://doi.org/10.1038/s41467-018-02939-0
6. Krishnamurthy J, Ramsey MR, Ligon KL et al (2006) p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 443(7110):453–457. https://doi.org/10.1038/nature05092
7. Galli A, Algerta M, Marciani P et al (2020) Shaping pancreatic β-cell differentiation and functioning: the influence of mechanotransduction. Cells 9(2). https://doi.org/10.3390/cells9020013
8. Dhawan S, Tschen SI, Zeng C et al (2015) DNA methylation directs functional maturation of pancreatic beta cells. J Clin Invest 125(7):2851–2860. https://doi.org/10.1172/jci79956
9. Kushner JA (2013) The role of aging upon beta cell turnover. J Clin Invest 123(3):990–995. https://doi.org/10.1172/jci64095
10. Brown ML, Schneyer AL (2010) Emerging roles for the TGFβ family in pancreatic beta-cell homeostasis. Trends Endocrinol Metab 21(7):441–448. https://doi.org/10.1016/j.tem.2010.02.008
11. Nurgazi D, Mickle Y, Moganti K et al (2015) TGF-β1, but not bone morphogenetic proteins, activates Smad1/5 pathway in primary human macrophages and induces expression of proatherogenic genes. J Immunol 194(2):709–718. https://doi.org/10.4049/jimmunol.1300272
12. Massague J (2012) TGFβ signalling in context. Nat Rev Mol Cell Biol 13(10):616–630. https://doi.org/10.1038/nrm3434
13. Smart NG, ApeIqvist AA, Gu X et al (2006) Conditional expression of Smad7 in pancreatic beta cells disrupts TGF-β/beta signaling and induces reversible diabetes mellitus. PLoS Biol 4(2):e39. https://doi.org/10.1371/journal.pbio.0040039
14. Gao Y, Zhang R, Dai S, Zhang X, Li X, Bai C (2019) Role of TGF-β/Smad pathway in the transcription of pancreas-specific genes during beta cell differentiation. Front Cell Dev Biol 7:351. https://doi.org/10.3389/fcell.2019.00351
15. Chang C (2016) Agonists and antagonists of TGF-β family ligands. Cold Spring Harbor Perspect Biol 8(8). https://doi.org/10.1101/cshperspect.a021932
16. Szweras M, Liu D, Partridge EA et al (2002) α2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling.

J Biol Chem 277(22):19991–19997. https://doi.org/10.1074/jbc.M112234200
17. Stefan N, Henning AM, Staiger H et al (2006) α2-Heremans-Schmidt glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29(4):853–857. https://doi.org/10.2337/diacare.29.04.06.dc05-1938
18. Haussler M, Schafer C, Osterwinter C, Jahnin-Dechent W (2009) The physiologic development of fetuin-a serum concentrations in children. Pediatr Res 66(6):660–664. https://doi.org/10.1203/PDR.0b013e3181bc3f60
19. Pal D, Dasgupta S, Kundu R et al (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 18(8):1279–1285. https://doi.org/10.1038/nm.2851
20. Stefan N, Haring HU (2013) Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med 19(4):394–395. https://doi.org/10.1038/nm.3116
21. Gerst F, Ludwig W, Kaiser G et al (2017) Metabolic crosstalk between fatty pancreas and fatty liver: effects on local inflammation and insulin secretion. Diabetologia. https://doi.org/10.1007/s00125-017-4385-1
22. Ludwig B, Ludwig S, Steffen A et al (2017) Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes. Proc Natl Acad Sci U S A 114(44):11745–11750. https://doi.org/10.1073/pnas.170820114
23. Kemter E, Cohrs CM, Schafer M et al (2017) INS-eGFP transgenic pigs: a novel reporter system for studying maturation, growth and vascularisation of neonatal islet-like cell clusters. Diabetologia 60(6):1152–1156. https://doi.org/10.1007/s00125-017-4250-2
24. Sakwe AM, Koumangoye R, Goodwin SJ, Ochieng J (2010) Fetuin-A α2HS-glycoprotein is a major serum adhesive protein that mediates growth signaling in breast tumor cells. J Biol Chem 285(53):41827–41835. https://doi.org/10.1074/jbc.M110.1128926
25. Cayatte AJ, Kumbia L, Subbiah MT (1990) Marked acceleration of exogenous fatty acid incorporation into cellular triglycerides by fetuin. J Biol Chem 265(10):5883–5888. https://doi.org/10.1016/S0021-9258(19)39445-1
26. Jahnen-Dechent W, Heiss A, Schafer C, Kettelk M (2011) Fetuin-A regulation of calcified matrix metabolism. Circ Res 108(12):1494–1509. https://doi.org/10.1161/circresaha.110.234260
27. Gerst F, Jaghutritz BA, Staiuer H et al (2018) The expression of aldolase B in islets is negatively associated with insulin secretion in humans. J Clin Endocrinol Metab 103(12):4373–4383. https://doi.org/10.1210/jc.2018-00791
28. Sachs S, Bastidas-Ponce A, Trischler S et al (2020) Targeted pharmacological therapy restores beta-cell function for diabetes remisssion. Nat Metab 2(2):192–209. https://doi.org/10.1038/s42255-020-0171-3
29. Chen F, Lin X, Xu P et al (2015) Nuclear export of Smads by RanBP3L regulates bone morphogenetic protein signaling and mesenchymal stem cell differentiation. Mol Cell Biol 35(10):1700–1711. https://doi.org/10.1128/mcb.00121-15
30. Nomura M, Zhu HL, Wang L, Morinaga H, Takayanagi R, Teramoto N (2014) SMAD2 disruption in mouse pancreatic beta cells leads to islet hyperplasia and impaired insulin secretion due to the attenuation of ATP-sensitive K+ channel activity. Diabetologia 57(1):157–166. https://doi.org/10.1007/s00125-013-3062-2
31. Velazco-Cruz L, Song J, Maxwell KG et al (2019) Acquisition of dynamic function in human stem cell-derived beta cells. Stem Cell Rep 12(2):351–365. https://doi.org/10.1016/j.stemcr.2018.12.012
32. Mueller KR, Balamarung AN, Cline GW et al (2013) Differences in glucose-stimulated insulin secretion in vitro of islets from human, nonhuman primate, and porcine origin. Xenotransplantation 20(2):75–81. https://doi.org/10.1111/xen.12022
33. Mourad NI, Perota A, Xhema D, Galli C, Gianello P (2017) Transgenic expression of glucagon-like Peptide-1 (GLP-1) and
activated muscarinic receptor (M3R) significantly improves pig islet secretory function. Cell Transplant 26(5):901–911. https://doi.org/10.3727/096368916X693798

34. Kin T, Korbutt GS, Kobayashi T, Dufour JM, Rajotte RV (2005) Reversal of diabetes in pancreatectomized pigs after transplantation of neonatal porcine islets. Diabetes 54(4):1032–1039. https://doi.org/10.2337/diabetes.54.4.1032

35. Wang JL, Corbett JA, Marshall CA, McDaniel ML (1993) Glucose-induced insulin secretion from purified beta-cells. A role for modulation of Ca²⁺ influx by cAMP- and protein kinase C-dependent signal transduction pathways. J Biol Chem 268(11):7785–7791. https://doi.org/10.1016/S0021-9258(18)53027-1

36. Speier S, Gjinovci A, Charollais A, Meda P, Rupnik M (2007) Cx36-mediated coupling reduces beta-cell heterogeneity, confines the stimulating glucose concentration range, and affects insulin release kinetics. Diabetes 56(4):1078–1086. https://doi.org/10.2337/db06-0232

37. Yagi K, Furuhashi M, Aoki H et al (2002) c-myc is a downstream target of the Smad pathway. J Biol Chem 277(1):854–861. https://doi.org/10.1074/jbc.M104170200

38. Laybutt DR, Weir GC, Kaneto H et al (2002) Overexpression of c-Myc in beta-cells of transgenic mice causes proliferation and apoptosis, downregulation of insulin gene expression, and diabetes. Diabetes 51(6):1793–1804. https://doi.org/10.2337/diabetes.51.6.1793

39. Cohrs CM, Panzer JK, Drotar DM et al (2020) Dysfunction of persisting β cells is a key feature of early type 2 diabetes pathogenesis. Cell Rep 31(1):107469. https://doi.org/10.1016/j.celrep.2020.03.033

40. Blodgett DM, Nowosieleska A, Afik S et al (2015) Novel observations from next-generation RNA sequencing of highly purified human adult and fetal islet cell subsets. Diabetes 64(9):3172–3181. https://doi.org/10.2337/db15-0039

41. Townsend SE, Gannon M (2019) Extracellular matrix-associated factors play critical roles in regulating pancreatic β-cell proliferation and survival. Endocrinology 160(8):1885–1894. https://doi.org/10.1210/en.2019-00206

42. Llacua LA, Faas MM, de Vos P (2018) Extracellular matrix molecules and their potential contribution to the function of transplanted pancreatic islets. Diabetologia 61(6):1261–1272. https://doi.org/10.1007/s00125-017-4524-8

43. Smid JK, Faulkes S, Rudnicki MA (2015) Periostin induces pancreatic regeneration. Endocrinology 156(3):824–836. https://doi.org/10.1210/en.2014-1637

44. Hess DA (2015) Periostin conditions the matrix to generate a niche for islet regeneration. Endocrinology 156(3):772–776. https://doi.org/10.1210/en.2015-1020

45. Mateus Goncalves L, Pereira E, Werneck de Castro JP, Bernal-Mizrachi E, Almada J (2020) Islet pericytes convert into profibrotic myofibroblasts in a mouse model of islet vascular fibrosis. Diabetologia 63(8):1564–1575. https://doi.org/10.1007/s00125-020-05168-7

46. Meier JJ, Butler AE, Saisho Y et al (2008) Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes 57(6):1584–1594. https://doi.org/10.2337/db07-1369

47. Dhawan S, Dirice E, Kulkarni RN, Bhushan A (2016) Inhibition of TGF-β signaling promotes human pancreatic β-cell replication. Diabetes 65(5):1208–1218. https://doi.org/10.2337/db15-1331

48. Shirakawa J, Fernandez M, Takatani T et al (2017) Insulin signaling regulates the FoxM1/PLK1/CENP-A pathway to promote adaptive pancreatic β cell proliferation. Cell Metab 25(4):868–882.e865. https://doi.org/10.1016/j.cmet.2017.02.004

49. Klochendler A, Caspi I, Corem N et al (2016) The genetic program of pancreatic beta-cell replication in vivo. Diabetes 65(7):2081–2093. https://doi.org/10.2337/db16-0003

50. Hall E, Jonsson J, Ofori JK et al (2019) Glucolipotoxicity alters insulin secretion via epigenetic changes in human islets. Diabetes 68(10):1965–1974. https://doi.org/10.2337/db18-0900

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.